Cargando…

Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients

Background and Objectives: Aspirin (ASA) is a commonly used antithrombotic drug that has been demonstrated to reduce venous thromboembolism. The aim was to analyze if geriatric COVID-19 patients undergoing a 100 mg/day Aspirin (ASA) treatment prior to hospitalization differ in hospital outcome compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zekri-Nechar, Khaoula, Barberán, José, Zamorano-León, José J., Durbán, María, Andrés-Castillo, Alcira, Navarro-Cuellar, Carlos, López-Farré, Antonio, López-de-Andrés, Ana, Jiménez-García, Rodrigo, Martínez-Martínez, Carlos H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694688/
https://www.ncbi.nlm.nih.gov/pubmed/36422187
http://dx.doi.org/10.3390/medicina58111649
_version_ 1784837865529671680
author Zekri-Nechar, Khaoula
Barberán, José
Zamorano-León, José J.
Durbán, María
Andrés-Castillo, Alcira
Navarro-Cuellar, Carlos
López-Farré, Antonio
López-de-Andrés, Ana
Jiménez-García, Rodrigo
Martínez-Martínez, Carlos H.
author_facet Zekri-Nechar, Khaoula
Barberán, José
Zamorano-León, José J.
Durbán, María
Andrés-Castillo, Alcira
Navarro-Cuellar, Carlos
López-Farré, Antonio
López-de-Andrés, Ana
Jiménez-García, Rodrigo
Martínez-Martínez, Carlos H.
author_sort Zekri-Nechar, Khaoula
collection PubMed
description Background and Objectives: Aspirin (ASA) is a commonly used antithrombotic drug that has been demonstrated to reduce venous thromboembolism. The aim was to analyze if geriatric COVID-19 patients undergoing a 100 mg/day Aspirin (ASA) treatment prior to hospitalization differ in hospital outcome compared to patients without previous ASA therapy. Materials and Methods: An observational retrospective study was carried out using an anonymized database including geriatric COVID-19 patients (March to April 2020) admitted to Madrid Hospitals Group. A group of COVID-19 patients were treated with low ASA (100 mg/day) prior to COVID-19 infection. Results: Geriatric ASA-treated patients were older (mean age over 70 years; n = 41), had higher frequency of hypertension and hyperlipidemia, and upon admission had higher D-dimer levels than non-ASA-treated patients (mean age over 73 years; n = 160). However, patients under ASA treatment did not show more frequent pulmonary thromboembolism (PE) than non-ASA-treated patients. ASA-treated geriatric COVID-19-infected patients in-hospital < 30 days all-cause mortality was more frequent than in non-ASA-treated COVID-19 patients. In ASA-treated COVID-19-infected geriatric patients, anticoagulant therapy with low molecular weight heparin (LMWH) significantly reduced need of ICU care, but tended to increase in-hospital < 30 days all-cause mortality. Conclusions: Prior treatment with a low dose of ASA in COVID-19-infected geriatric patients increased frequency of in-hospital < 30 days all-cause mortality, although it seemed to not increase PE frequency despite D-dimer levels upon admission being higher than in non-ASA users. In ASA-treated geriatric COVID-19-infected patients, addition of LMWH therapy reduced frequency of ICU care, but tended to increase in-hospital < 30 days all-cause mortality.
format Online
Article
Text
id pubmed-9694688
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96946882022-11-26 Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients Zekri-Nechar, Khaoula Barberán, José Zamorano-León, José J. Durbán, María Andrés-Castillo, Alcira Navarro-Cuellar, Carlos López-Farré, Antonio López-de-Andrés, Ana Jiménez-García, Rodrigo Martínez-Martínez, Carlos H. Medicina (Kaunas) Article Background and Objectives: Aspirin (ASA) is a commonly used antithrombotic drug that has been demonstrated to reduce venous thromboembolism. The aim was to analyze if geriatric COVID-19 patients undergoing a 100 mg/day Aspirin (ASA) treatment prior to hospitalization differ in hospital outcome compared to patients without previous ASA therapy. Materials and Methods: An observational retrospective study was carried out using an anonymized database including geriatric COVID-19 patients (March to April 2020) admitted to Madrid Hospitals Group. A group of COVID-19 patients were treated with low ASA (100 mg/day) prior to COVID-19 infection. Results: Geriatric ASA-treated patients were older (mean age over 70 years; n = 41), had higher frequency of hypertension and hyperlipidemia, and upon admission had higher D-dimer levels than non-ASA-treated patients (mean age over 73 years; n = 160). However, patients under ASA treatment did not show more frequent pulmonary thromboembolism (PE) than non-ASA-treated patients. ASA-treated geriatric COVID-19-infected patients in-hospital < 30 days all-cause mortality was more frequent than in non-ASA-treated COVID-19 patients. In ASA-treated COVID-19-infected geriatric patients, anticoagulant therapy with low molecular weight heparin (LMWH) significantly reduced need of ICU care, but tended to increase in-hospital < 30 days all-cause mortality. Conclusions: Prior treatment with a low dose of ASA in COVID-19-infected geriatric patients increased frequency of in-hospital < 30 days all-cause mortality, although it seemed to not increase PE frequency despite D-dimer levels upon admission being higher than in non-ASA users. In ASA-treated geriatric COVID-19-infected patients, addition of LMWH therapy reduced frequency of ICU care, but tended to increase in-hospital < 30 days all-cause mortality. MDPI 2022-11-15 /pmc/articles/PMC9694688/ /pubmed/36422187 http://dx.doi.org/10.3390/medicina58111649 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zekri-Nechar, Khaoula
Barberán, José
Zamorano-León, José J.
Durbán, María
Andrés-Castillo, Alcira
Navarro-Cuellar, Carlos
López-Farré, Antonio
López-de-Andrés, Ana
Jiménez-García, Rodrigo
Martínez-Martínez, Carlos H.
Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients
title Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients
title_full Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients
title_fullStr Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients
title_full_unstemmed Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients
title_short Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients
title_sort analysis of prior aspirin treatment on in-hospital outcome of geriatric covid-19 infected patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694688/
https://www.ncbi.nlm.nih.gov/pubmed/36422187
http://dx.doi.org/10.3390/medicina58111649
work_keys_str_mv AT zekrinecharkhaoula analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients
AT barberanjose analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients
AT zamoranoleonjosej analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients
AT durbanmaria analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients
AT andrescastilloalcira analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients
AT navarrocuellarcarlos analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients
AT lopezfarreantonio analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients
AT lopezdeandresana analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients
AT jimenezgarciarodrigo analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients
AT martinezmartinezcarlosh analysisofprioraspirintreatmentoninhospitaloutcomeofgeriatriccovid19infectedpatients